Epix resubmits NDA for magnetic resonance angiography agent
If approved, Vasovist will be the first contrast agent approved for marketing in the US for use with magnetic resonance angiography (MRA), a non-invasive modality for imaging blood
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Foundation Radiology Group’s (FRG) board certified radiologists are available 24/7/365 to provide readings in muscularskeletal radiology, neuroradiology, mammography, cardiac CT, interventional radiology, pediatric radiology, brain perfusion, vascular ultrasound,